🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus

RecruitingPhase 4Ages 18 Years - anyAllChinese University of Hong Kong
NCT06364930 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a five-year, double blinded, randomised trial of dapagliflozin versus placebo in patients with chronic hepatitis B and DM or IFG complicated with compensated advanced chronic liver disease (cACLD). 412 subjects will be recruited. Subject will be randomly assigned to receive dapagliflozin 10mg daily or dapagliflozin placebo one tablet daily for up to 5 years. After randomization, subject will be followed up at month 3, month 6 and then 6-monthly until 60 months (follow up ± 4 weeks from scheduled clinic visit is allowed). At each visit, drug compliance, physical examination, observed or reported adverse events will be assessed. 10ml of blood will be taken at each visit and transient elastography to assess fibrosis regression will be performed at 60th month or at withdrawal visit. You are discouraged to use (pegylated)-interferon, any other NA including lamivudine, adefovir, and te

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients with chronic hepatitis B on ETV, TDF or TAF monotherapy for at least 12 months. 2. Known or newly diagnosed type 2 diabetes mellitus (T2D), defined as HbA1c ≥5.7% or fasting blood sugar ≥5.6 mmol/L, or random blood sugar ≥11.1 mmol/L, or 2 hours sugar after oral glucose tolerance test ≥7.8 mmol/L. 3. Stable use of anti-diabetic drugs in the last three months. 4. Presence of compensated advanced chronic liver disease (cACLD) with liver stiffness measurement \>10.0 kPa, or significant portal hypertension (spleen stiffness measurement \> 41.3 kPa), or presence any sign of portal hypertension (e.g. splenomegaly, ascites, varices) 5. Aged 18 years old or above. 6. Written informed consent obtained. Exclusion Criteria: 1. Patients with hepatitis C virus (HCV) infection as indicated by a positive antibody to HCV (anti-HCV) serology test. 2. Patients with history of cirrhotic complications or hepatocellular carcinoma 3. Patients with organ transplantation 4. Patients receiving a SGLT2i 5. Contraindications to SGLT2i due to renal insufficiency (GFR \< 45 mL/min/1.73m2) 6. Poor glycaemic control with HbA1c \>9.0% 7. Use of multiple anti-diabetic drugs (3 or more) 8. Change in anti-diabetic drugs in the last three months. 9. Serious medical illnesses or malignancy 10. Age \< 18 years 11. No patient consents
💊

What it tests

  • Dapagliflozin 10mg Tab
  • Placebo 10mg Tab
📍

Where

1 site
Prince of Wales Hospital
Hong Kong, Hong Kong
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy